Compare AARD & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AARD | EARN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 169.8M |
| IPO Year | 2025 | 2012 |
| Metric | AARD | EARN |
|---|---|---|
| Price | $6.07 | $4.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $15.29 | $5.38 |
| AVG Volume (30 Days) | 116.4K | ★ 400.2K |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 20.51% |
| EPS Growth | ★ 43.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $4.25 |
| 52 Week High | $17.94 | $5.77 |
| Indicator | AARD | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 41.03 |
| Support Level | $5.12 | $4.29 |
| Resistance Level | $6.43 | $4.48 |
| Average True Range (ATR) | 0.83 | 0.07 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 36.65 | 5.00 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.